Compare TKC & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKC | ORKA |
|---|---|---|
| Founded | 1993 | 2004 |
| Country | Turkey | United States |
| Employees | N/A | 68 |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.5B |
| IPO Year | 2001 | N/A |
| Metric | TKC | ORKA |
|---|---|---|
| Price | $5.57 | $91.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $92.50 |
| AVG Volume (30 Days) | ★ 2.2M | 1.3M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.20 | N/A |
| Revenue Next Year | $24.27 | N/A |
| P/E Ratio | $26.98 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.35 | $12.84 |
| 52 Week High | $7.18 | $97.78 |
| Indicator | TKC | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 59.84 |
| Support Level | $5.54 | $80.94 |
| Resistance Level | $6.07 | $97.78 |
| Average True Range (ATR) | 0.09 | 4.97 |
| MACD | -0.02 | -0.32 |
| Stochastic Oscillator | 16.51 | 69.26 |
Turkcell Iletisim Hizmetleri AS provides mobile telephone services in Turkey. The firm's services portfolio includes mobile and fixed voice, data, TV, and digital services over its network. The firm also operates in the Turkish Republic of Northern Cyprus, Belarus, the Netherlands, and Ukraine. It has three main reportable segments: Turkcell Turkiye, Techfin, and Other. The Turkcell Turkiye segment, which derives the majority of revenue, comprises mainly telecommunication and technology services activities.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.